Skip to main content
. Author manuscript; available in PMC: 2015 Apr 9.
Published in final edited form as: Heart Lung. 2014 Dec 24;44(2):129–136. doi: 10.1016/j.hrtlng.2014.07.007

Table 4.

Performance of device observations including OptiVol in stratifying patients at risk of heart failure hospitalization (HFH).

Number of device observation(s) Number of follow-ups (number of patients) Number of HFHs (%) GEE adjusted HFHs (95% CI) Odds ratio versus 0 observation (95% CI)
0 1103 (554) 4 (0.4) 0.4% (0.1-1.0) Reference group
1 828 (514) 14 (1.7) 1.7% (0.9-3.0) 4.6 (1.4-14.5)
2 279 (190) 15 (5.4) 5.3% (3.1 -8.8) 14.9 (5.2-43.1)
≥3 66 (50) 9 (13.6) 13.6% (7.2-24.3) 42.4 (12.6-142.1)